News

Filter

7001 to 7010 of 97249 results

US Pharma execs most concerned about the changing commercial business model

04-12-2012

Results of a new survey illustrate evolutions on business models, next generation technical trends and…

ManagementNorth AmericaPharmaceutical

Another Alzheimer's drug hits the dust as Bristol-Myers drops avagacestat development

04-12-2012

In yet another research disappointment, US drug major Bristol-Myers Squibb (NYSE: BMY) recently assessed…

avagacestatbapineuzumabBristol-Myers SquibbMK-8931NeurologicalPharmaceuticalResearchsolanezumab

Pharma R&D internal rate of return falls for a second year but shows signs of stabilizing

04-12-2012

The R&D internal rate of return (IRR) of leading pharmaceutical companies has fallen for a second successive…

BiotechnologyFinancialPharmaceuticalResearch

Merck Serono collaborates with Neopharma for production in UAE

04-12-2012

Merck Serono, a division of Germany's Merck KGaA (MRK: DE), Germany, and Unite Arab Emirates drug manufacturer…

DiabetesEuthyroxGlucophageGlucophage XRMerck KGaAMerck SeronoNeopharmaPharmaceuticalProductionRest of the WorldWomen's Health

AstraZeneca inks deal for Optimer's fidaxomicin in Latin America

04-12-2012

USA-based Optimer Pharmaceuticals (Nasdaq: OPTR) says it has executed an exclusive agreement with Anglo-Swedish…

Antibiotics and Infectious diseasesAstraZenecafidaxomicinLicensingOptimer PharmaceuticalsPharmaceuticalSouth America

US Congressman Cassidy, et al, propose drug shortage solutions

03-12-2012

US Congressman Bill Cassidy, a medical physician (Republican, Louisiana) and four colleagues, last week…

GenericsHealthcareLegalNorth AmericaPharmaceutical

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra

03-12-2012

Vertex Pharmaceuticals (Nasdaq: VRTX) says that Health Canada has approved Kalydeco (ivacaftor), the…

BiotechnologyKalydecoMenactraNorth AmericaPharmaceuticalRare diseasesRegulationSanofiSanofi PasteurVaccinesVertex

Merck & Co moves Alzheimer's candidate MK-8931 into Ph II/III

03-12-2012

US drug giant Merck & Co (NYSE: MRK) says it has started a Phase II/III clinical trial designed to evaluate…

Merck & CoMK-8931NeurologicalPharmaceuticalResearch

PharmaEssentia gets certain Asian rights to Kinex' dermatology candidate KX01

03-12-2012

USA-based privately-held Kinex Pharmaceuticals has entered a licensing agreement granting Taiwan's PharmaEssentia…

Asia-PacificBiotechnologyDermatologicalsKinex PharmaceuticalsKX01LicensingPharmaEssentia

7001 to 7010 of 97249 results

Back to top